IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤内科
学科主题临床医学
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences
Ren, Jun1; Di, Lijun1; Song, Guohong1; Yu, Jing1; Jia, Jun1; Zhu, Yuling1; Yan, Ying1; Jiang, Hanfang1; Liang, Xu1; Che, Li1; Zhang, Jie1; Wan, Fengling1; Wang, Xiaoli1; Zhou, Xinna1; Lyerly, Herbert Kim1,2
关键词Metastatic breast cancer High-dose chemotherapy Immunotherapy Dendritic cells Cytokine-induced killers
刊名CLINICAL & TRANSLATIONAL ONCOLOGY
2013-10-01
DOI10.1007/s12094-013-1001-9
15期:10页:780-788
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]PHASE-III TRIAL ; RANDOMIZED-TRIAL ; STEM-CELLS ; ADJUVANT TREATMENT ; TRANSPLANTATION ; IMMUNOTHERAPY ; SUPPORT ; DOCETAXEL ; THIOTEPA ; DENSE
英文摘要

We hypothesized that combination of dendritic cell (DC) with autologous cytokine-induced killer (CIK) immunotherapy in setting of high-dose chemotherapy (HDC) would be effective for selected metastatic breast cancer (MBC) patients.

Our previous work showed thiotepa could eradicate breast cancer stem cells. From 2004 to 2009, 79 patients received standard dose chemotherapy (SDC) of 75 mg/m(2) docetaxel and 75 mg/m(2) thiotepa versus 87 patients of HDC + DC/CIK: 120 mg/m(2) docetaxel to mobilize peripheral CD34(+) progenitor cells, a sequence of HDC (120 mg/m(2) docetaxel, plus 175 mg/m(2) thiotepa) + DC/CIK, with or without 400 mg/m(2) carboplatin depending upon bone marrow function. The endpoints were response rates (RR), progression-free survival (PFS), and overall survival (OS).

Compared with SDC, PFS and OS were improved in HDC + DC/CIK (median PFS 10.2 vs. 3.7 months, P < 0.001; median OS 33.1 vs. 15.2 months, P < 0.001). Patients of pre-menopausal, HDC as first-line treatment after metastasis, or with visceral metastasis showed prolonged PFS and OS. SDC group also achieved the similar response as previous reports.

Our study demonstrated the novel combination of HDC with DC/CIK to be an effective choice for the selected MBC population, in which choosing appropriate chemo regimens played important roles, and also specific HDC regimen plus DC/CIK immunotherapy showed the clinical benefits compared with chemotherapy alone.

语种英语
WOS记录号WOS:000324556600004
引用统计
被引频次:19[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66654
专题北京大学临床肿瘤学院_肿瘤内科
北京大学公共卫生学院_妇女与儿童青少年卫生学系
北京大学临床肿瘤学院_乳腺肿瘤内科
北京大学临床肿瘤学院_移植与免疫治疗病区
作者单位1.Peking Univ, Canc Hosp & Inst, Dept Med Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Duke Univ, Med Ctr, Durham, NC 27710 USA
推荐引用方式
GB/T 7714
Ren, Jun,Di, Lijun,Song, Guohong,et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences[J]. CLINICAL &amp; TRANSLATIONAL ONCOLOGY,2013,15(10):780-788.
APA Ren, Jun.,Di, Lijun.,Song, Guohong.,Yu, Jing.,Jia, Jun.,...&Lyerly, Herbert Kim.(2013).Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences.CLINICAL & TRANSLATIONAL ONCOLOGY,15(10),780-788.
MLA Ren, Jun,et al."Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences".CLINICAL & TRANSLATIONAL ONCOLOGY 15.10(2013):780-788.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ren, Jun]的文章
[Di, Lijun]的文章
[Song, Guohong]的文章
百度学术
百度学术中相似的文章
[Ren, Jun]的文章
[Di, Lijun]的文章
[Song, Guohong]的文章
必应学术
必应学术中相似的文章
[Ren, Jun]的文章
[Di, Lijun]的文章
[Song, Guohong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。